Veracyte Inc. (VCYT)
NASDAQ: VCYT
· Real-Time Price · USD
26.44
-0.17 (-0.64%)
At close: Jun 02, 2025, 10:15 AM
-0.64% (1D)
Bid | 19.26 |
Market Cap | 2.07B |
Revenue (ttm) | 463.39M |
Net Income (ttm) | 33.05M |
EPS (ttm) | 0.42 |
PE Ratio (ttm) | 62.95 |
Forward PE | 37.43 |
Analyst | Buy |
Ask | 33.57 |
Volume | 109,586 |
Avg. Volume (20D) | 1,039,520 |
Open | 26.57 |
Previous Close | 26.61 |
Day's Range | 26.05 - 27.13 |
52-Week Range | 19.73 - 47.32 |
Beta | 2.15 |
About VCYT
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol VCYT
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for VCYT stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts3 months ago
+0.46%
Veracyte shares are trading lower. The company rep...
Unlock content with
Pro Subscription
6 months ago
+2.05%
Veracyte shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY24 sales guidance. Needham and UBS maintained Buy ratings and raised their respective price targets on the stock.

1 month ago · businesswire.com
Veracyte Announces Expanded Availability of Decipher Prostate Test to Patients with Metastatic Prostate CancerSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte Announces Expanded Availability of Decipher Prostate Test to Patients with Metastatic Prostate Cancer.